Srikant Rangaraju, MD; Kumiko Owada, MD; Ali Reza Noorian, MD; et al.
free access
has audio
JAMA Neurol. 2013;70(7):831-836. doi:10.1001/jamaneurol.2013.413
In a retrospective cohort study, Rangaraju and coauthors assess whether patients with intracranial large-vessel occlusions who received intra-arterial therapy have smaller final infarct volumes than patients who received either intravenous tissue plasminogen activator therapy or no reperfusion therapy. See the by Adams and Froehler.
-
Podcast:
Comparison of Final Infarct Volumes in Patients Who Received Endovascular Therapy or Intravenous Thrombolysis for Acute Intracranial Large-Vessel Occlusions
Niaz Ahmed, MD; Lars Kellert, MD; Kennedy R. Lees, MD; et al.
free access
JAMA Neurol. 2013;70(7):837-844. doi:10.1001/jamaneurol.2013.406
In an observational study based on Safe Implementation of Treatment in Stroke International Stroke Thrombolysis Register (SITS-ISTR) data during the period from 2002 to 2011, Ahmed and coauthors compare outcomes of patients who were treated within 4.5 to 6 hours or within 3 to 4.5 hours of the onset of an ischemic stroke with outcomes of patients who were treated within 3 hours in the SITS-ISTR.
Eva M. Palacios; Roser Sala-Llonch; Carme Junque, PhD; et al.
free access
JAMA Neurol. 2013;70(7):845-851. doi:10.1001/jamaneurol.2013.38
Palacios et al studied functional magnetic resonance imaging abnormalities in signal amplitude and brain connectivity at rest and their relationship to cognitive outcome in patients with chronic and severe traumatic axonal injury.
Lama M. Chahine, MD; Judy Qiang, BA; Emily Ashbridge; et al.
free access
JAMA Neurol. 2013;70(7):852-858. doi:10.1001/jamaneurol.2013.1274
To determine if patients having PD with vs without GBA mutations differ in clinical phenotype or plasma protein expression, Chahine et al performed a case-control study. Clinical characteristics were compared between groups, and biochemical profiling of 40 plasma proteins was performed to identify proteins that differed in expression between groups.
Rodolfo Savica, MD, MSc; Brandon R. Grossardt, MS; James H. Bower, MD, MSc; et al.
free access
JAMA Neurol. 2013;70(7):859-866. doi:10.1001/jamaneurol.2013.114
Savica et al investigate the incidence and distribution of specific types of parkinsonism and related proteinopathies in the general population.
Stephanie Cosentino, PhD; Nicole Schupf, PhD; Kaare Christensen, PhD; et al.
free access
JAMA Neurol. 2013;70(7):867-874. doi:10.1001/jamaneurol.2013.1959
Cosentino et al determine whether families with exceptional longevity are protected against cognitive impairment consistent with Alzheimer disease.
Rita Guerreiro, PhD; Eleanna Kara, MD, MSc; Isabelle Le Ber, MD, PhD; et al.
free access
JAMA Neurol. 2013;70(7):875-882. doi:10.1001/jamaneurol.2013.698
Guerreiro et al sequenced a large cohort of adult-onset leukodystrophy cases to better understand the genetic role of mutations in CSF1R.
Seth D. Friedman, PhD; Laura D. Baker, PhD; Soo Borson, MD; et al.
free access
JAMA Neurol. 2013;70(7):883-890. doi:10.1001/jamaneurol.2013.1425
Friedman et al used brain magnetic resonance spectroscopy to examine the neurochemical effects of growth hormone–releasing hormone in adults with mild cognitive impairment and in healthy older adults.
Olivier Andlauer, MD; Hyatt Moore IV, MSc; Laura Jouhier, MD; et al.
free access
JAMA Neurol. 2013;70(7):891-902. doi:10.1001/jamaneurol.2013.1589
Andlauer et al determine the diagnostic accuracy and clinical utility of nocturnal rapid eye movement sleep latency measures in narcolepsy/hypocretin deficiency.
Vincent Doré, PhD; Victor L. Villemagne, MD; Pierrick Bourgeat, PhD; et al.
free access
JAMA Neurol. 2013;70(7):903-911. doi:10.1001/jamaneurol.2013.1062
Doré et al investigated the topographical relationship of Aβ deposition, gray matter atrophy, and memory impairment in asymptomatic individuals with Alzheimer disease pathology as assessed by Pittsburgh compound B positron emission tomography.